Bionano Genomics, Inc. (BNGO) — Financial statements
Income statement, balance sheet, and cash flow for Bionano Genomics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 29↓7.4% | 31↓14.8% | 36↑29.9% | 28↑54.6% | 18 | |
| Cost of Revenue | 22↓26.8% | 30↑14.5% | 27↑21.5% | 22↑54.9% | 14 | |
| Gross Profit | 6↑1546.8% | 0.38↓96.0% | 10↑60.9% | 6↑53.5% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 11↓54.1% | 25↓54.1% | 54↑10.2% | 49↑118.1% | 22 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 28↓45.6% | 52↓45.4% | 95↑7.2% | 89↑51.5% | 58 | |
| Other Expenses | 0.00↓100.0% | 28↓63.5% | 76 | 0.00 | 0.00 | |
| Operating Expenses | 40↓62.1% | 104↓53.6% | 225↑63.3% | 138↑70.0% | 81 | |
| Total Costs & Expenses | 62↓54.1% | 135↓46.4% | 251↑57.6% | 160↑67.7% | 95 | |
| Operating Results | ||||||
| Operating Income | -33↑67.9% | -104↑51.7% | -215↓63.4% | -132↓70.8% | -77 | |
| Depreciation & Amortization | 10↓31.6% | 14↑3.8% | 14↑35.7% | 10↑199.7% | 3 | |
| EBITDA | -24↑75.8% | -97↑54.4% | -214↓77.5% | -120↓62.9% | -74 | |
| EBIT | -33↑70.2% | -112↑50.9% | -227↓74.3% | -130↓68.9% | -77 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.81↓55.1% | 2↑200.2% | -2↓249.5% | 1↑275.0% | -0.69 | |
| Interest Income | 1↓47.1% | 2↓36.5% | 3↑119.7% | 2↑538.6% | 0.24 | |
| Interest Expense | 0.30↑3.1% | 0.29↓94.4% | 5↑1617.8% | 0.30↓67.9% | 0.93 | |
| Non-Operating Income | 0.00↓100.0% | 8↓36.1% | 12↑1039.8% | -1↓1135.5% | 0.12 | |
| Other Income / Expenses | 7↑187.6% | -8↑53.4% | -17↓1843.0% | 0.99↑193.8% | -1 | |
| Income Before Tax | -26↑76.5% | -112↑51.8% | -232↓77.8% | -131↓67.3% | -78 | |
| Income Tax Expense | 0.07↑103.0% | 0.03↓46.8% | 0.06↓96.7% | 2↑133.0% | -6 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -26↑76.4% | -112↑51.8% | -232↓75.3% | -133↓83.1% | -72 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -26↑76.4% | -112↑51.8% | -232↓75.3% | -133↓83.1% | -72 | |
| Bottom-Line Net Income | -26↑76.4% | -112↑51.8% | -232↓75.3% | -133↓83.1% | -72 | |
| EPS (Basic) | -4.85↑94.5% | -88.13↑78.4% | -408.48↓52.6% | -267.71↓70.5% | -157.02 | |
| EPS (Diluted) | -4.85↑94.5% | -88.13↑78.4% | -408.60↓52.6% | -267.71↓70.5% | -157.02 | |
| Weighted Average Shares | 5↑186.2% | 2↑227.8% | 0.58↑18.0% | 0.49↑4.5% | 0.47 | |
| Weighted Average Diluted Shares | 5↑186.2% | 2↑227.7% | 0.58↑18.1% | 0.49↑4.5% | 0.47 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.